PeterWeidenMD

Summary

• Peter J Weiden MD is a psychiatrist based in New York City with subspecialties in neuropsychiatry, psychopharmacology, and clinical pharmacology. He completed his psychiatry residency at New York Presbyterian Hospital and holds an MS in Psychiatric Epidemiology from Columbia University. Dr. Weiden is currently a Clinical Professor of Psychiatry at Stony Brook University and leads a clinical trials program in new treatments for major psychiatric disorders at Richmond Behavioral Associates (RBA) in Staten Island. Before that he was a VP of Medical at Karuna Therapeutics between 2020-2023 where he was part of the Phase 3 Clinical Development program of the muscarinic agonist xanomeline/trospium approved as COBENFY in September 2024. His clinical expertise covers pand ost-traumatic stress disorder, schizophrenia, ADHD, and bipolar disorders. Dr. Weiden has also been involved in clinical trials like PREvent First Episode Relapse (PREFER) and was recognized among the Top Doctors in the New York Metro Area by Castle Connolly from 2002 to 2006.